The Value-for-Money of Adjuvant Aromatase Inhibitors: Time to Put the Debate to Rest?

T. Younis; A. Groom

doi:10.3747/co.22.2579

You are currently viewing a new version of our website. To view the old version click .

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Editorial

1 April 2015

The Value-for-Money of Adjuvant Aromatase Inhibitors: Time to Put the Debate to Rest?

and

Dalhousie University, Department of Medicine, QE II Health Sciences Centre, Halifax, NS, Canada

Author to whom correspondence should be addressed.

Curr. Oncol.2015, 22(2), 77-79;https://doi.org/10.3747/co.22.2579

Version Notes

Order Reprints

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

The adoption of costly treatments in public health care systems, such as exists in Canada, must take into account their “clinical benefit to side effect” profiles and “value for money” in an attempt to maximize health gains within current budget constraints [...]

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Canadian Cancer Screening Disparities: A Recent Historical Perspective

Ethnicity and Breast Cancer Stage at Diagnosis: An Issue of Health Equity